Tirzepatide and pregnancy: what the FDA label says, why weight-loss shots are stopped before conception, and safer options for blood sugar control.
Tirzepatide is not recommended during pregnancy. The FDA-approved labels for Mounjaro and Zepbound instruct patients to stop the medication as soon as pregnancy is recognized, and intentional weight loss is not advised during pregnancy. If you are pregnant, trying to conceive, or breastfeeding, contact your prescriber before your next dose.
What the FDA Label Says About Tirzepatide and Pregnancy
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Neither product is approved for use in pregnancy, and no randomized human trials have shown it is safe for a developing fetus.
Animal reproduction studies found fetal harm at clinically relevant exposures, including reduced fetal weight and changes in skeletal development. Researchers cannot translate animal findings directly into human risk, but the signal is strong enough that regulators recommend against use.
- Stop tirzepatide when pregnancy is recognized.
- Weight loss is not recommended during pregnancy, even for people with obesity.
- Tirzepatide is not a treatment for gestational diabetes.
What to Do in Different Situations
The right next step depends on where you are in the process. The table below summarizes the most common scenarios.
| Situation | Recommended action |
|---|---|
| Planning a pregnancy | Talk with your prescriber before you try to conceive; most clinicians advise stopping tirzepatide and switching to a pregnancy-compatible plan. |
| Just found out you are pregnant | Hold your next dose and contact your prescriber or OB right away. A single recent dose is not the same as months of exposure. |
| Pregnant and still taking tirzepatide | Discontinue the medication and ask about safer options for blood sugar or blood pressure control. |
| Breastfeeding | Tirzepatide is not recommended while breastfeeding because of the potential for serious reactions, including weight loss, in the infant. |
| Male partner using tirzepatide | Human data on paternal exposure is limited; discuss it with a clinician if you are trying to conceive. |
Fertility, Contraception, and Timing
Tirzepatide is not a contraceptive. Weight loss can improve ovulation, especially in people with polycystic ovary syndrome, so pregnancy can happen when it previously did not.
Tirzepatide also slows gastric emptying, which can reduce how well oral birth control pills are absorbed. The label advises using a non-oral contraceptive or adding a barrier method while taking the drug.
Tirzepatide has a half-life of about five days, so it takes roughly four to five weeks to clear your system. Many clinicians suggest stopping at least one to two months before conception, but no official waiting period has been established. Ask your prescriber what timing fits your situation.
Breastfeeding and Postpartum Use
There is no human data on how much tirzepatide passes into breast milk or how it affects a nursing infant. Because the drug is designed to reduce appetite and body weight, the concern is that a breastfed baby could experience weight loss or other serious effects.
Manufacturers advise against using tirzepatide while breastfeeding. If weight management is a priority after delivery, ask your clinician about nutrition, physical activity, and non-drug options that are compatible with nursing.
Safer Options During and After Pregnancy
For diabetes in pregnancy, insulin and metformin have decades of safety data and remain the standard choices. Gestational diabetes is managed with medical nutrition therapy, glucose monitoring, and medication when needed, not with GLP-1 drugs.
Questions about glutathione and pregnancy often come up alongside weight-loss injections, but most fat-loss supplements and peptides have little or no pregnancy safety data. Skip anything your OB has not reviewed.
Compounded Tirzepatide and Unapproved Combinations
Compounded tirzepatide contains the same active ingredient as the brand-name products, so the pregnancy guidance does not change. Compounded drugs are not FDA-approved for safety, quality, or effectiveness, which adds another layer of uncertainty.
Other injectables sold for weight loss, such as lipo-c and tirzepatide, carry the same caution in pregnancy, and some lipotropic formulas contain ingredients that are not considered safe for a fetus.
Searches for aod 9604 and tirzepatide together usually reflect interest in stacking fat-loss compounds. Neither has pregnancy safety data, and unregulated peptides introduce unknown risks to both the pregnant person and the fetus.
People also ask can you take semaglutide and tirzepatide at the same time to speed up results. Combining them is not recommended at any point, and neither belongs in a pregnancy plan.
The tirzepatide and semaglutide difference comes down to mechanism: tirzepatide targets GIP and GLP-1, while semaglutide targets GLP-1 only. Both carry the same core warning that they are not recommended during pregnancy.
The Bottom Line
- Tirzepatide is not recommended for use during pregnancy, and the label directs patients to stop it as soon as pregnancy is recognized.
- Weight loss is not recommended in pregnancy, so the main purpose of tirzepatide does not apply.
- Tirzepatide is not recommended while breastfeeding.
- Anyone planning a pregnancy should talk with their prescriber about stopping tirzepatide before conception.
- This article is general information, not medical advice; your OB and prescriber should guide your care.
Frequently Asked Questions
Can I get pregnant while taking tirzepatide?
Yes. Tirzepatide is not a contraceptive, and weight loss can actually improve fertility in some people, especially those with polycystic ovary syndrome. Because the drug is not recommended in pregnancy, use reliable birth control — and remember that tirzepatide can make oral contraceptive pills less effective, so a backup or non-oral method is wise.
How long should I wait to get pregnant after stopping tirzepatide?
No official waiting period has been established. Tirzepatide has a half-life of about five days, so it takes roughly four to five weeks to leave your system, and many clinicians suggest waiting one to two months after the last dose before trying to conceive. Confirm the timing with your prescriber.
Does tirzepatide cause birth defects?
Animal studies show fetal harm, including reduced fetal weight and skeletal changes, at clinically relevant doses. Human data is too limited to confirm or rule out a risk. That uncertainty is why the label recommends stopping the drug if pregnancy occurs.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.